natgillin/translations-raw huggingface dataset:
A field study involved 6 farms with a history of S. uberis clinical mastitis and recently confirmed presence of S. uberis infection.
Terenska študija je vključevala šest kmetij, na katerih se je v preteklosti že pojavil klinični mastitis zaradi bakterije S. uberis in na katerih je bila pred kratkim potrjena okužba z bakterijo S. uberis.
Ubac is a vaccine.
Zdravilo UBAC je cepivo.
If someone is accidentally injected with this product, they must seek medical attention immediately even if only a very small amount is injected.
V primeru nenamernega injiciranja cepiva je treba nemudoma poiskati zdravniško pomoč, četudi je bila morda injicirana zelo majhna količina.
When Ubac is given to cattle, the animals' immune system recognises the active susbstance as ‘foreign' and makes antibodies against it.
Ko goveda prejmejo zdravilo UBAC, imunski sistem živali prepozna učinkovino kot „tujek“ ter začne proti njej tvoriti protitelesa.
Ubac is also used to reduce the somatic cell count (SCC) in milk, which is a measure of mastitis without visible signs (subclinical mastitis).
Zdravilo UBAC se uporablja tudi za zmanjšanje števila somatskih celic v mleku, ki so pokazatelj mastitisa brez vidnih znakov (subkliničnega mastitisa).
Ubac contains the active substance called biofilm adhesion component including lipoteichoic acid, which is derived from the sticky film produced by Streptococcus uberis strain 5616.
Zdravilo UBAC vsebuje učinkovino, imenovano komponenta lepljivega biofilma, ki vsebuje lipoteihojsko kislino, pridobljeno iz lepljivega filma, ki ga proizvaja sev 5616 bakterije Streptococcus uberis.
Ubac is available as an injection and can only be obtained with a prescription.
Zdravilo UBAC je na voljo v obliki injekcije, njegovo predpisovanje in izdaja pa je le na recept.
The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption.
Karenca je čas, ki mora preteči po dajanju zdravila, preden se lahko žival zakolje in meso uporabi za prehrano ljudi.
The most common side effects with UBAC (which may affect more than 1 in 10 animals) are a shortlived increase in rectal temperature of around 1 - 2 ºC within 24 hours of injection and a local injection site swelling of more than 5 cm in diameter.
Najpogostejša neželena učinka zdravila UBAC (ki lahko prizadeneta več kot 1 žival od 10) sta kratkotrajno povišanje rektalne temperature za približno 1-2 °C v 24 urah po injiciranju in oteklina na mestu injiciranja s premerom več kot 5 cm. Oteklina na mestu injiciranja navadno izgine ali se njena velikost zmanjša v 17 dneh po cepljenju, v nekaterih primerih pa oteklina lahko traja do štiri tedne.
How is Ubac used?
Kako se zdravilo UBAC uporablja?
How does Ubac work?
Kako zdravilo UBAC deluje?
4 pre-filled syringes
4 napolnjene injekcijske brizge
Subcutaneous use pre-filled syringe 1 ml (50 mg/ml) 12 (3 x 4) pre-filled syringes (multipack)
1 ml (50 mg/ml) 12 (3 x 4) napolnjenih injekcijskih brizg (večodmerno pakiranje)
Subcutaneous use pre-filled syringe 1 ml (50 mg/ml) 4 pre-filled syringes
1 ml (50 mg/ml) 4 napolnjene injekcijske brizge
Subcutaneous use pre-filled pen 1 ml (50 mg/ml) 4 pre-filled pens
1 ml (50 mg/ml) 4 napolnjeni injekcijski peresniki
The effects were sustained for up to seven years.
Učinki so se ohranili do sedem let.
This summary was last updated in 03-2014.
Povzetek je bil nazadnje posodobljen 03-2014.
The European Commission granted a marketing authorisation valid throughout the European Union for Siklos on 29 June 2007.
Evropska komisija je dovoljenje za promet z zdravilom Siklos, veljavno po vsej Evropski uniji, izdala 29. junija 2007.
Siklos is taken once a day, preferably in the morning before breakfast.
Zdravilo Siklos se jemlje enkrat dnevno, po možnosti zjutraj pred zajtrkom.
The number of cases of acute chest syndrome also fell by 25 to 33%.
Tudi število primerov akutnega prsnega sindroma se je zmanjšalo za 25 do 33 %.
It is available as tablets (100 and 1,000 mg).
Na voljo je v obliki tablet (100 in 1 000 mg).
What measures are being taken to ensure the safe and effective use of Siklos?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Siklos?
Hydroxycarbamide, which used to be known as hydroxyurea, has been available in the European Union (EU) for several decades for use in other illnesses, including some types of cancer.
Hidroksikarbamid, nekdaj znan kot hidroksisečnina, je v Evropski uniji (EU) že nekaj desetletij na voljo za uporabo pri drugih boleznih, vključno z nekaterimi vrstami raka.
The 1,000 mg tablet has special score lines so that it can be easily divided into four equal parts.
1 000-miligramska tableta ima posebne zareze, ki omogočajo enostavno razdelitev na štiri enake dele.
Blood cell counts normally return to normal within two weeks of stopping Siklos treatment.
Število krvnih celic se na normalno raven običajno vrne v dveh tednih po prenehanju zdravljenja z zdravilom Siklos.
Patients who do not respond to this dose or who have side effects may need to stop or suspend treatment.
Pri bolnikih, ki se ne odzivajo na ta odmerek ali imajo neželene učinke, bo morda treba zdravljenje prenehati ali prekiniti.
There were also fewer admissions into hospital, and fewer days spent in hospital.
Zmanjšalo se je tudi število sprejemov v bolnišnico in bolnišničnih dni.
For more information about treatment with Siklos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Siklos preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Siklos is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Siklos je bil pripravljen načrt obvladovanja tveganj.
In particular, it presented evidence on the effectiveness of Siklos from 11 published studies involving 378 children and from three national registries of information on 155 children with sickle cell syndrome who were treated with Siklos for up to seven years.
Predstavila je predvsem dokaze o učinkovitosti zdravila Siklos iz 11 objavljenih študij s 378 otroki in treh nacionalnih registrov s podatki o 155 otrocih s srpastoceličnim sindromom, ki so zdravilo Siklos prejemali do sedem let.
The summary of the opinion of the Committee for Orphan Medicinal Products for Siklos can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Povzetek mnenja Odbora za zdravila sirote o zdravilu Siklos je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
In the study comparing Siklos with placebo in adults, there were fewer vaso-occlusive crises in the patients taking Siklos (2.5 crises per year) than in those taking placebo (4.5 crises per year).
V študiji, v kateri so pri odraslih primerjali zdravilo Siklos s placebom, so zabeležili manj vazookluzivnih kriz pri bolnikih, ki so jemali zdravilo Siklos (2,5 krize na leto), kot pri tistih, ki so prejemali placebo (4,5 krize na leto).
This reduces the risk of blood vessels becoming blocked.
To zmanjša tveganje za zamašitev krvnih žil.
This is a summary of the European public assessment report (EPAR) for Siklos.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Siklos.
The starting dose is usually 15 mg per kilogram body weight, using the most appropriate tablet strengths (100 or 1,000 mg) to make up the dose, breaking up the 1,000-mg tablet in quarters (250 mg) if needed.
Začetni odmerek je običajno 15 mg na kilogram telesne mase, uporabi pa se najprimernejša jakost tablete (100 ali 1 000 mg) za pripravo odmerka, pri čemer se po potrebi 1 000-miligramska tableta zlomi na četrtine (250 mg).
Patients had fewer vaso-occlusive crises when treated with Siklos than before treatment, with the frequency falling by between 66% and 80% in children and adults.
Bolniki, ki so prejemali zdravilo Siklos, so imeli po zdravljenju manj vazookluzivnih kriz kot pred njim, pri čemer se je njihova pogostnost pri otrocih in odraslih zmanjšala za 66 % do 80 %.
Siklos is a medicine that contains the active substance hydroxycarbamide.
Siklos je zdravilo, ki vsebuje zdravilno učinkovino hidroksikarbamid.
The studies compared the number of vaso-occlusive crises before and after treatment with Siklos, as defined by any painful episode involving the arms, legs, abdomen, back or chest.
V študijah so primerjali število vazookluzivnih kriz pred zdravljenjem z zdravilom Siklos in po njem, pri čemer so se te kazale z bolečimi epizodami v rokah, nogah, trebuhu, hrbtu ali prsnem košu.
Because hydroxycarbamide is a well-known substance that is already used in other medicines, the company used data from the scientific literature to support the use of Siklos in adults and children with sickle cell syndrome.
Ker je hidroksikarbamid dobro znana učinkovina, ki se uporablja tudi v drugih zdravilih, je družba uporabila podatke iz znanstvene literature za podporo uporabe zdravila Siklos pri odraslih in otrocih s srpastoceličnim sindromom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Siklos.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The most common side effect with Siklos (seen in more than one patient in 10) is bone marrow suppression, causing neutropenia (low levels of neutrophils, a type of white blood cell), reticulocytopenia (low levels of reticulocytes, a type of immature red blood cell) and macrocytosis (enlargement of red blood cells).
Najpogostejši neželen učinek zdravila Siklos (opažen pri več kot 1 bolniku od 10) je supresija kostnega mozga, ki povzroča nevtropenijo (nizke ravni nevtrofilcev, vrste belih krvnih celic), retikulocitopenijo (nizke ravni retikulocitov, vrste nezrelih rdečih krvnih celic) in makrocitozo (povečanje rdečih krvnih celic).
Because the number of patients with sickle cell syndrome is low, the disease is considered ‘rare', and Siklos was designated an ‘orphan medicine' (a medicine used in rare diseases) on 9 July 2003.
Ker je bolnikov s srpastoceličnim sindromom malo, velja ta bolezen za redko, zato je bilo zdravilo Siklos dne 9. julija 2003 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
What benefit has Siklos shown during the studies?
Kakšne koristi je zdravilo Siklos izkazalo med raziskavami?
The CHMP decided that Siklos's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Siklos večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
What is the risk associated with Siklos?
Kakšna tveganja so povezana z zdravilom Siklos?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Siklos, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Siklos in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
They can include acute chest syndrome, a life-threatening condition when the patient has sudden chest pain, fever, hard breathing or signs of fluid in the lungs on an X ray.
Vključujejo lahko akutni prsni sindrom, tj. življenjsko nevarno stanje, ko se pri bolniku pojavijo nenadne bolečine v prsih, vročina, oteženo dihanje ali znaki tekočine v pljučih pri rentgenskem slikanju.
The company that makes Siklos will also provide information packs for doctors and for patients describing the safety information on the medicine.
Družba, ki izdeluje zdravilo Siklos, bo za zdravnike in bolnike pripravilo informativne brošure z informacijami o varnosti zdravila.
The full EPAR for Siklos can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Siklos je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It also presented evidence from one study in 299 adults, in which the effects of Siklos were compared with those of placebo (a dummy treatment), as well as the results of other studies involving 430 adults and one national registry of information on 123 adults treated with Siklos.
Predstavljeni so bili tudi podatki iz študije, ki je zajela 299 odraslih in primerjala učinke zdravila Siklos z učinki placeba (zdravila brez zdravilne učinkovine), kot tudi rezultati drugih študij, v katerih je sodelovalo 430 odraslih, ter podatki iz enega nacionalnega registra z informacijami o 123 odraslih, zdravljenih z zdravilom Siklos.
Other information about Siklos
Druge informacije o zdravilu Siklos:
Although the precise way that it works in this disease is not understood, hydroxycarbamide can reduce the numbers of cells that are circulating in the blood, as well as prevent red blood cells changing shape in patients with sickle cell syndrome.
Čeprav natančen način delovanja hidroksikarbamida pri tej bolezni ni znan, lahko zmanjša število celic, ki krožijo v krvi, ter prepreči spreminjanje oblike rdečih krvnih celic pri bolnikih s srpastoceličnim sindromom.
The active substance in Siklos, hydroxycarbamide, blocks the growth and reproduction of some cells, such as blood cells.
Zdravilna učinkovina zdravila Siklos, hidroksikarbamid, zavira rast in reprodukcijo nekaterih celic, npr. krvnih celic.
Treatment with Siklos should be started by a doctor who has experience in the management of sickle cell syndrome.
Zdravljenje z zdravilom Siklos mora uvesti zdravnik, ki ima izkušnje z zdravljenjem srpastoceličnega sindroma.
Patients taking Siklos should have blood tests before and regularly during treatment, to check their blood cell counts and also to monitor their kidneys and liver.
Pri bolnikih, ki jemljejo zdravilo Siklos, je treba pred zdravljenjem in redno tudi med njim izvajati krvne preiskave za preverjanje števila krvnih celic ter spremljanje delovanja ledvic in jeter.
Siklos must not be used in people who have severe problems with their kidneys or liver, or who have dangerously low blood cell counts.
Zdravilo Siklos se ne sme uporabljati pri bolnikih, ki imajo resne težave z ledvicami ali jetri ali ki imajo nevarno nizke ravni krvnih celic.
Siklos, reversible oligospermia or azoospermia (reduced or absent production of healthy sperm) is also very commonly seen.
Pri moških, zdravljenih z zdravilom Siklos, sta zelo pogosto opaženi reverzibilni oligospermija ali azoospermija (zmanjšano ali odsotno nastajanje zdrave sperme).
Breast-feeding must be stopped while taking Siklos.
Med jemanjem zdravila Siklos je treba prenehati dojiti.
It is used to prevent recurrent, painful vaso-occlusive crises that happen when blood vessels become blocked by the abnormal red blood cells, restricting the flow of blood to an organ.
Uporablja se za preprečevanje vazookluzivnih kriz, ki nastanejo, ko nenormalne rdeče krvne celice zamašijo krvne žile in s tem omejijo pretok krvi do organa.
For the full list of all side effects reported with Siklos, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Siklos, glejte navodilo za uporabo.
Siklos is used in adults, adolescents and children over two years of age who have sickle cell syndrome, a genetic disease where the red blood cells become rigid and sticky, and change from being discshaped to being crescent-shaped (like a sickle).
Zdravilo Siklos se uporablja pri odraslih, mladostnikih in otrocih, starejših od dveh let, ki imajo srpastocelični sindrom, tj. gensko bolezen, pri kateri rdeče krvne celice postanejo toge in spremenijo obliko iz okroglo-ploščate v srpasto.
Why has Siklos been approved?
Zakaj je bilo zdravilo Siklos odobreno?
How does Siklos work?
Kako zdravilo Siklos deluje?
How has Siklos been studied?
Kako je bilo zdravilo Siklos raziskano?
The dose is adjusted according to the response to treatment, with the usual dose being between 15 and 30 mg per kilogram body weight per day.
Odmerek se prilagodi glede na odziv na zdravljenje, običajni odmerek pa je med 15 in 30 mg na kilogram telesne mase na dan. Odmerki do 35 mg na kilogram telesne mase na dan se smejo uporabljati le izjemoma, pri čemer se mora izvajati nadzor bolnikove krvi glede morebitnih neželenih učinkov.
What is Siklos used for?
Za kaj se zdravilo Siklos uporablja?
The dose of Siklos should be reduced in patients who have mild or moderate problems with their kidneys.
Pri bolnikih, ki imajo blage ali zmerne težave z ledvicami, bo odmerek zdravila Siklos morda treba zmanjšati.
How is Siklos used?
Kako se zdravilo Siklos uporablja?
What is Siklos?
Kaj je zdravilo Siklos?
Symptoms were reversible.
Simptomi so bili reverzibilni.
The recommended dose should not be exceeded.
Priporočenega odmerka ne smete prekoračiti.
The tablet can be divided into equal halves.
Tableto se lahko razdeli na dve enaki polovici.
ΑΘηνών - Λαμίαζ, 14452, Μεταμόρυωση, Αττική Τηλ.
ΑΘηνών - Λαμίαζ, 14452, Μεταμόρφωση, Αττική Τηλ.
The precision of the syringe is not suitable for the treatment of cats below 1 kg.
Natančnost brizge ni primerna za zdravljenje mačk pod 1 kg.
Maximum number of piercings is 42 for all presentations.
Največje število prebadanj zamaška je 42 za vse predstavitve
Accidental self-injection may give rise to pain.
Nenamerno samoinjiciranje lahko povzroči bolečino.
The active substance in Inflacam is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010:
Učinkovina zdravila Inflacam je dovoljena učinkovina kot je navedena v tabeli 1(dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
PVC/PVDC blister packs with a 20 micron foil.
PVC / PVDC pretisni omoti z 20 mikronsko folijo.
To ensure correct dosage, body weight should be determined as accurately as possible to avoid underdosing or overdosing.
Da bi zagotovili pravilno odmerjanje, je treba telesno težo določiti čim bolj natančno, da bi se izognili prenizkemu ali previsokemu odmerjanju.
Please carefully follow the instructions of the veterinarian.
Ravnajte natančno po veterinarjevih navodilih.
Bottle (HDPE)
Plastenka (HDPE)
If the animal is fed at the time of dosing, the absorption may be slightly delayed.
Če žival ob dajanju zdravila nahranimo, se njegova absorpcija nekoliko zakasni.
See also section 4.7.
Glejte tudi poglavje 4.7.
In order to minimise risk of intolerance, the product should be mixed into muesli feed.
Da bi zmanjšali tveganje intolerance, je treba zdravilo vmeša v müsli krmo.
For example, a horse weighing 400 kg will receive 16 ml of Inflacam, a horse weighing 500 kg will receive 20 ml of Inflacam, and a horse weighing 600 kg will receive 24 ml of Inflacam.
Na primer, konj, ki tehta 400 kg, bo prejel 16 ml Inflacama, konj, ki tehta 500 kg, bo prejel 20 ml Inflacama in konj, ki tehta 600 kg, bo prejel 24 ml za Inflacama.
Reduction of post-operative pain (over a period of 24 hours):
Lajšanje pooperativne bolečine (v 24-urnem obdobju):
Milk: 5 days.
Mleko: 5 dni
Purified water
prečiščena voda
The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.
Faktor kopičenja 1,08 kaže, da se meloksikam pri vsakodnevnem dajanju ne kopiči.
15 μg/kg Milk
15 μg/kg mleko
Avoid introduction of contamination during use.
Preprečite, da bi med uporabo prišlo do kontaminacije.
One ml contains:
En ml vsebuje:
Inflacam alone will not provide adequate pain relief during the dehorning procedure.
Samo zdravilo Inflacam ne zagotavlja ustreznega lajšanja bolečine med postopkom odstranjevanja rogov.
Shelf life after incorporation into muesli feed: use immediately.
Rok uporabnosti po vključitvi v müsli krmo: uporabite takoj.
This product is only for use in horses weighing between 500 and 600 kg.
To zdravilo je samo za uporabo pri konjih, ki tehtajo med 500 in 600 kg.
Cattle, pigs and horses
Govedo, prašiči in konji
Number of chewable tablets mg/kg
Število žvečlijivih tablet mg/kg
When the product is used according to the recommended dosage regime, the oral bioavailability is approximately 98%.
Če dajemo zdravilo po priporočeni shemi odmerjanja, je njegova peroralna biološka uporabnost približno 98-odstotna.
For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Inflacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.
Za daljše zdravljenje, ko je klinični odziv že opazen (po ≥ 4 dneh), se odmerek Inflacama lahko prilagodi na najnižji individualni odmerek, ki učinkuje na zmanjšanje bolečine in vnetja pri kroničnih mišično skeletnih obolenj, ki se s časom lahko spremeni.
In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.
Če zdravilo dajemo zamešano v hrano, ga moramo dodati majhni količini hrane pred hranjenjem.
During anaesthesia, monitoring and fluid therapy should be considered as standard practice.
Med anestezijo je treba upoštevati rutinsko spremljane in tekočinsko terapijo kot standardno prakso.
Paper foil sachets (paper/PE/alu/PE) containing 1.5 g granules per sachet in a cardboard box.
Vrečice papir folije (papir/PE/alu/PE), ki vsebuje 1,5 g zrnc na vrečico v kartonasti škatli.
VIRBAC Sp. o.o.
Polska VIRBAC Sp. o.o.
Chronic musculoskeletal disorders: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.
Kronična mišično-skeletna obolenja: Odzivanje na dolgotrajno zdravljenje mora v rednih razmikih spremljati veterinar.
For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.
Pri zdravljenju driske pri govedu,ne uporabite pri živalih, mlajših od enega tedna.
A clinical response is normally seen within 7 days.
Klinični odziv na zdravljenje je običajno opazen po 7 dneh.
The syringe has a scale which corresponds to the volume required.
Brizga ima merilno skalo, ki ustreza zahtevanemu volumnu.
The product should be added to 250 g of muesli feed, prior to feeding.
Zdravilo je treba dodati 250 g müsli krme pred hranjenjem.
Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
Ob začetku terapije, na prvi dan zdravljenja, je torej potreben dvakratni volumen vzdrževalnega odmerka.
In horses, a transient swelling at the injection site can occur but resolves without intervention.
Pri konjih se lahko na mestu vboda pojavi prehodna oteklina, ki mine brez intervencije.
The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.
Prostornina porazdelitve je 0,3 l/kg pri psih in 0,09 l/kg pri mačkah.
This is equivalent to 1 ml of Inflacam per 25 kg body weight of horse.
To je enakovredno 1 ml Inflacama na 25 kg telesne mase konja.
A one ml syringe is provided with the product.
Ena ml brizga je priložena zdravilu.
This product for dogs should not be used in cats as it is not suitable for use in this species.
Tega zdravila za pse se ne sme uporabljati pri mačkah, ker za to živalsko vrsto ni primerno za uporabo.
A clinical response is normally seen within 3 to 4 days.
Klinični odziv na zdravljenje je običajno opazen po 3 do 4 dneh.
Maximal plasma concentrations are obtained after approximately 2-3 hours.
Največjo koncentracijo v plazmi doseže približno po 2 do 3 urah.
The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion.
Prisotnost presnovkov matične spojine v urinu in blatu, ne pa v plazmi, kaže na hitro izločanje.
Meloxicam is predominantly found in plasma.
Meloksikam se pretežno nahaja v plazmi.
Pale yellow granules.
Bledo rumena zrnca.